Tag:
George Scangos
Latest Headlines
Latest Headlines
Fast-growing Biogen Idec bursts the seams at new Cambridge HQ
When George Scangos took the helm at Biogen Idec, he left little doubt that he couldn't much stand the company's gleaming new headquarters in Weston, MA, the brainchild of ex-CEO Jim Mullen. R&D in Cambridge was where it was at, and that's where he spent the bulk of his time.
UPDATED: Biogen CEO Scangos scores 19% pay hike during stellar 2012
Biogen Idec CEO George Scangos took home one of the largest pay packages in the biotech industry in 2012--a total of $13.45 million in 2012, a 19% jump in pay from his $11.33 million pay package the previous year, the Weston, MA-based company reported Monday in a proxy statement.
Teva tries to slow arrival of Biogen's competing MS blockbuster
With $4 billion of Copaxone revenue on the line, it's no surprise to find Teva waving a red flag to the FDA as Biogen Idec gets down to the regulatory wire with its closely watched competitor BG-12. The big generics company filed a petition with the FDA demanding an advisory committee meeting to inspect what it has called potentially "serious safety risks."
Biogen asks FDA for approval of first drug in potential $1B franchise
Biogen Idec has shipped its application to the FDA for approval of an experimental therapy for the rare bleeding disorder hemophilia B. And the long-lasting clotting factor is the most advanced candidate in what could become the Weston, MA-based biotech giant's next blockbuster business.
Biogen CEO Scangos hit with first big setback as ALS drug fails PhIII
Biogen Idec CEO George Scangos gambled big that dexpramipexole could buck the long losing streak of experimental drugs for ALS and go on to score positive results in Phase III. But today the company had to acknowledge that Scangos--in his first big setback after taking the helm--lost that wager.
Cambridge market sizzles as biotech ditches the burbs
Like pioneers rushing for gold, biotech and pharma outfits have swept into Cambridge, MA, and dismissed the hefty property costs in search of talent and technology that could lead to lucrative new drugs.
Biogen embraces Isis again in early-stage collaboration worth up to $630M
Less than a year after Biogen Idec inked its first development pact with the antisense experts at Isis Pharmaceuticals, the big biotech has come back to the bargaining table to sign off on their third deal, with Biogen paying $30 million upfront and promising up to $200 million more in milestones for each of three new programs aimed at neurological diseases and neuromuscular disorders.
Why George Scangos deserves credit for Biogen's hot streak
Industry watchers argue that Scangos deserves kudos for the success of the biotech powerhouse since his tenure began, Forbes editor Matthew Herper writes in a feature on the chief executive's impact.
Blockbuster buzz: 15 top therapies in late-stage development
The Holy Grail of every big R&D organization on the planet remains finding and developing blockbuster drugs. Breaking into the 10-figure club can be a defining moment in any researcher's career. It may not make it on the tombstone--here lies John T. Researcher, he developed a billion-dollar therapy--but it would be an understandable desire. Despite rumors to the contrary, the blockbuster is far from dead. Here are 15 hopefuls that are alive and kicking >>
Blockbuster buzz: 15 top therapies in late-stage development
The Holy Grail of every big R&D organization on the planet remains finding and developing blockbuster drugs. Breaking into the 10-figure club can be a defining moment in any researcher's career. It may not make it on the tombstone--here lies John T. Researcher, he developed a billion-dollar therapy--but it would be an understandable desire to carve it in. Despite rumors to the contrary, the blockbuster is far from dead. Here are 15 hopefuls that are alive and kicking >>
